projects:workgroups:clinicalstudy
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revisionNext revision | Previous revision | ||
| projects:workgroups:clinicalstudy [2024/04/28 20:17] – zhen | projects:workgroups:clinicalstudy [2025/05/11 15:58] (current) – mikehamidi | ||
|---|---|---|---|
| Line 10: | Line 10: | ||
| **Status**: | **Status**: | ||
| - | - 2022: CTWG was given access to 20 Vivli clinical study packages in the SDTM format. The CTWG team is doing an inventory of those study packages | + | - 2025: CTWG is providing new chapter content (Clinical Trial Data) for the upcoming Book of OHDSI update. |
| - | - 2021: CTWG did an assessment of clinical trial data providers | + | - 2024: The finalization of C-Path SDTM-to-OMOP mappings is underway, with an emphasis on matching concept codes using Usagi. The next step is to execute ETL queries to generate the OMOP CDM tables. Additionally, |
| + | - 2023: The team has transitioned from using Vivli (due to access constraints) data to leveraging SDTM data provided by C-Path for tuberculosis. The development of mapping specifications for the subsequent ETL process will proceed from the initial stages.\\ | ||
| + | - 2022: CTWG has been granted | ||
| + | - 2021: CTWG conducted | ||
| - 2020: Used a synthetic representation of the CDISC SDTM data via PHUSE Test Data. Initial guidance topics were codified but require further testing with diverse real world SDTM data. The CTWG proposals submitted to the OHDSI community in July 2020.\\ | - 2020: Used a synthetic representation of the CDISC SDTM data via PHUSE Test Data. Initial guidance topics were codified but require further testing with diverse real world SDTM data. The CTWG proposals submitted to the OHDSI community in July 2020.\\ | ||
| </ | </ | ||
| Line 25: | Line 28: | ||
| https:// | https:// | ||
| - | Recent WG Updates: [[https:// | + | Recent WG Updates: |
| + | [[https:// | ||
| ---- | ---- | ||
| ==== Meetings ==== | ==== Meetings ==== | ||
| - | {{: | ||
| - | **Bi-weekly | + | **Bi-weekly |
| *** Note on accessing Teams channel: | *** Note on accessing Teams channel: | ||
| Line 42: | Line 45: | ||
| **WG co-leads**: | **WG co-leads**: | ||
| - | Mike Hamidi, | + | Open Spot |
| and | and | ||
| - | TBD | + | Kenneth Wilkins |
| + | **WG past leads**: | ||
| + | Mike Hamidi, Tom Walpole, Zhen Li, Sonia Araujo | ||
| **Active members**\\ | **Active members**\\ | ||
| Line 55: | Line 60: | ||
| | Melissa Cook | Essex Management | | Melissa Cook | Essex Management | ||
| | Diane Corey | | Diane Corey | ||
| - | | Shital Desai | + | | Shital Desai |
| - | | Kerry Goetz | National Institute of Health; \\ National Eye Institute | + | | Kerry Goetz | National Institute of Health; \\ National Eye Institute |
| - | | Priya Gopal | Flatiron Health | + | | Mike Hamidi |
| - | | Mike Hamidi | + | | Dan Hartley |
| - | | Dan Hartley | + | |
| | Ying Huang | | Ying Huang | ||
| | Asiyah Yu Lin | National Institute of Health | | Asiyah Yu Lin | National Institute of Health | ||
| Line 66: | Line 70: | ||
| | Terrence McHugh | | Terrence McHugh | ||
| | Priya Meghrajani | | Priya Meghrajani | ||
| - | | Pam Nesbitt | ||
| | Paul Orona | | Paul Orona | ||
| | Daniel Olson | Critical Path Institute | | Daniel Olson | Critical Path Institute | ||
projects/workgroups/clinicalstudy.1714335431.txt.gz · Last modified: by zhen
